The life sciences sector currently represents the largest source of capital markets transactions for existing public companies. IPO activity and follow-on financing are two more ways to generate returns in biotech and healthcare.
Biotech fund portfolio manager and chemical biologist, Mark Charest gives a six-minute “master class” on the topic: